In-vitro and in-silico evaluation of Brugmansia sauveolens' ability to treat asthma

Abstract

Asthma is a common chronic inflammatory disease of the airways. The airway epithelium produces bioactive cellular mediators that trigger the chronic inflammatory response. These mediators then attract and activate inflammatory cells in the airways of the lungs and release more biochemical mediators. With several benefits, such as a significant reduction in the cost and time of drug discovery as well as the use of laboratory animals, in-silico studies have grown to be an important and simple method for examining various chemical compounds against various targets. One of the common herbs found in the local Himalayan area is Brugmansia sauveolens, known as Datura, which is a source of tropane alkaloids and asthma can be effectively managed with alkaloids. Using a Soxhlet extractor, the collected plant components were first extracted with petroleum ether (to remove fats) followed by methanol. Online technologies like PASS Online, Molinspiration, SEA, SWISS, and SLAP data were used for a variety of in-silico predictions. After that, we tested the ability of Brugmansia extracts to reduce inflammation using an in-vitro approach. Rat RBC membrane lyses were stabilized using the plant extract fractions. The outcomes were also compared with aspirin (a common anti-inflammatory drug). Bioinformatics techniques were used to detect structural activity. After investigating all the data It was shown that B. sauveolens had anti-asthmatic activity.